Immuneering (IMRX) Competitors

MediWound (NASDAQ:MDWD) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, community ranking, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

Is MDWD or IMRX more profitable?

Immuneering has a net margin of 0.00% compared to MediWound's net margin of -142.29%. Immuneering's return on equity of -79.19% beat MediWound's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediWound	-142.29%	-82.17%	-33.67%
Immuneering	N/A	-79.19%	-69.08%

Do analysts recommend MDWD or IMRX?

MediWound presently has a consensus price target of $31.33, suggesting a potential upside of 88.19%. Immuneering has a consensus price target of $11.00, suggesting a potential upside of 548.97%. Given Immuneering's higher possible upside, analysts clearly believe Immuneering is more favorable than MediWound.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediWound	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Immuneering	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Which has more volatility & risk, MDWD or IMRX?

MediWound has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, Immuneering has a beta of -0.32, meaning that its share price is 132% less volatile than the S&P 500.

Do insiders and institutionals hold more shares of MDWD or IMRX?

46.8% of MediWound shares are held by institutional investors. Comparatively, 67.7% of Immuneering shares are held by institutional investors. 9.2% of MediWound shares are held by insiders. Comparatively, 25.0% of Immuneering shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Does the MarketBeat Community favor MDWD or IMRX?

MediWound received 362 more outperform votes than Immuneering when rated by MarketBeat users. However, 68.63% of users gave Immuneering an outperform vote while only 62.23% of users gave MediWound an outperform vote.

Company	Underperform	Outperform
MediWound	Outperform Votes 397 62.23%	Underperform Votes 241 37.77%
Immuneering	Outperform Votes 35 68.63%	Underperform Votes 16 31.37%

Does the media prefer MDWD or IMRX?

In the previous week, MediWound had 13 more articles in the media than Immuneering. MarketBeat recorded 25 mentions for MediWound and 12 mentions for Immuneering. MediWound's average media sentiment score of 0.34 beat Immuneering's score of -0.07 indicating that MediWound is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MediWound	2 Very Positive mention(s)	5 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Immuneering	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has higher valuation and earnings, MDWD or IMRX?

MediWound has higher revenue and earnings than Immuneering. MediWound is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediWound	$20.22M	8.89	-$6.72M	-$3.07	-5.42
Immuneering	$320K	164.47	-$53.47M	-$2.03	-0.83

Summary

Immuneering beats MediWound on 9 of the 17 factors compared between the two stocks.